Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Cardio Green
2. Cardio-green
3. Green, Indocyanine
4. Indocyanine Green
5. Ujoveridin
6. Vofaverdin
7. Vophaverdin
8. Wofaverdin
1. Indocyanine Green
2. 3599-32-4
3. Cardio-green
4. Foxgreen
5. Mfcd00013078
6. Sodium;4-[(2e)-2-[(2e,4e,6e)-7-[1,1-dimethyl-3-(4-sulfonatobutyl)benzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]butane-1-sulfonate
7. Indocyaninegreen
8. Sodium 4-(2-(7-(1,1-dimethyl-3-(4-sulfonatobutyl)-1h-benzo[e]indol-2(3h)-ylidene)hepta-1,3,5-trien-1-yl)-1,1-dimethyl-1h-benzo[e]indol-3-ium-3-yl)butane-1-sulfonate
9. 1h-benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4-sulfobutyl)-2h-benz[e]indol-2-ylidene]-1,3,5-heptatrienyl]-1,1-dimethyl-3-(4-sulfobutyl)-, Inner Salt, Sodium Salt
10. Cardiogreen, For Microscopy
11. Cardiogreen, Polymethine Dye
12. Schembl16027582
13. Akos015896404
14. Akos016010308
15. As-11023
16. I0535
17. A823083
18. Q905662
19. Indocyanine Green, United States Pharmacopeia (usp) Reference Standard
20. Sodium 4-[(2e)-2-[(2e,4e,6e)-7-[1,1-dimethyl-3-(4-sulfonatobutyl)-2-benzo[e]indol-3-iumyl]hepta-2,4,6-trienylidene]-1,1-dimethyl-3-benzo[e]indolyl]-1-butanesulfonate
21. Sodium 4-[(2e)-2-[(2e,4e,6e)-7-[1,1-dimethyl-3-(4-sulfonatobutyl)benzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethyl-benzo[e]indol-3-yl]butane-1-sulfonate
Molecular Weight | 775.0 g/mol |
---|---|
Molecular Formula | C43H47N2NaO6S2 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 12 |
Exact Mass | 774.27732385 g/mol |
Monoisotopic Mass | 774.27732385 g/mol |
Topological Polar Surface Area | 137 Ų |
Heavy Atom Count | 54 |
Formal Charge | 0 |
Complexity | 1520 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 4 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Ic-green |
Drug Label | ICGREEN is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide. It is packaged with Aqueous Solvent consisting of Sterile Water for Injection used to dissolve the indocyanine green. IC... |
Active Ingredient | Indocyanine green |
Dosage Form | Injectable |
Route | Injection |
Strength | 25mg/vial |
Market Status | Prescription |
Company | Akorn |
2 of 4 | |
---|---|
Drug Name | Indocyanine green |
Drug Label | ICGREEN is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide. It is packaged with Aqueous Solvent consisting of Sterile Water for Injection used to dissolve the indocyanine green. IC... |
Active Ingredient | Indocyanine green |
Dosage Form | Injectable |
Route | Injection |
Strength | 25mg/vial |
Market Status | Prescription |
Company | Pulsion Medcl |
3 of 4 | |
---|---|
Drug Name | Ic-green |
Drug Label | ICGREEN is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide. It is packaged with Aqueous Solvent consisting of Sterile Water for Injection used to dissolve the indocyanine green. IC... |
Active Ingredient | Indocyanine green |
Dosage Form | Injectable |
Route | Injection |
Strength | 25mg/vial |
Market Status | Prescription |
Company | Akorn |
4 of 4 | |
---|---|
Drug Name | Indocyanine green |
Drug Label | ICGREEN is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide. It is packaged with Aqueous Solvent consisting of Sterile Water for Injection used to dissolve the indocyanine green. IC... |
Active Ingredient | Indocyanine green |
Dosage Form | Injectable |
Route | Injection |
Strength | 25mg/vial |
Market Status | Prescription |
Company | Pulsion Medcl |
Dyes
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
TO DETERMINE CARDIAC OUTPUT, HEPATIC FUNCTION, & LIVER BLOOD FLOW. FOR HEPATIC FUNCTION STUDIES, CALCULATED AMT OF DIAGNOSTIC AGENT IS INJECTED INTO ARM VEIN. 20 MIN AFTER INJECTION, 6 ML OF VENOUS BLOOD IS WITHDRAWN FROM OPPOSITE ARM. AFTER COAGULATION & CENTRIFUGATION, CLEAR SERUM IS READ IN PHOTOMETER @ 800-810 NM.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1214
DYE RETENTION OF LESS THAN 4% IS FOUND IN HEALTHY SUBJECTS. ... FAILURE TO REMOVE DYE, AS INDICATED BY SERUM LEVELS IN EXCESS OF 4%, IS INDICATIVE OF IMPAIRED HEPATIC FUNCTION.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1214
USUAL, IV, BLOOD VOL DETERMINATION, 5 MG IN 1 ML; HEPATIC FUNCTION DETERMINATION, 0-5 MG/KG.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1214
DYE IS STABLE IN PLASMA & WHOLE BLOOD PERMITTING LATER ANALYSIS. USERS VARY BOTH CONCN & DOSAGE. IN MAN TOTAL DOSAGE HAS NORMALLY BEEN BELOW 2 MG/KG.
Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 275
...CONTAINS SMALL AMT OF /5%/ SODIUM IODIDE; THUS, IT SHOULD BE USED WITH CAUTION IN PT ALLERGIC TO IODIDES & RADIOACTIVE IODINE UPTAKE STUDIES SHOULD NOT BE PERFORMED FOR AT LEAST 1 WK FOLLOWING ITS USE. SINCE PROBENECID HAS BEEN SHOWN IN DOGS TO AFFECT HEPATIC UPTAKE, THIS POSSIBILITY SHOULD BE KEPT IN MIND.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1214
SAFE USE OF THIS DRUG IN PREGNANCY HAS NOT BEEN ESTABLISHED.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1214
USE FRESH SOLN ONLY AS RECOMMENDED.
Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 275
Coloring Agents
Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. (See all compounds classified as Coloring Agents.)
V - Various
V04 - Diagnostic agents
V04C - Other diagnostic agents
V04CX - Other diagnostic agents
V04CX01 - Indocyanine green
FOLLOWING IV INJECTION, INDOCYANINE GREEN IS RAPIDLY BOUND TO PLASMA PROTEIN, QUICKLY REMOVED FROM CIRCULATION BY LIVER, & EXCRETED IN BILE IN UNCONJUGATED FORM.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1214
WITH INDOCYANINE GREEN, IT HAS BEEN SHOWN THAT RAT HAS HIGHER MAX BILIARY EXCRETION RATE (0.065 MG/KG/MIN) THAN DOES RABBIT (0.05 MG/KG/MIN) OR DOG (0.027 MG/KG/MIN).
LaDu, B.N., H.G. Mandel, and E.L. Way. Fundamentals of Drug Metabolism and Disposition. Baltimore: Williams and Wilkins, 1971., p. 139
T/2 INCR WITH INCR DOSAGE. ... CONSIDERABLE DIFFERENCE HAS BEEN NOTED BETWEEN NORMAL MONGRELS & PUREBRED BEAGLES IN CLEARANCE TIMES.
Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 275
APPARENT HEPATIC EXTRACTION OF INDOCYANINE GREEN IN RATS WAS SURPRISINGLY LOW @ DOSES ABOVE 1 MG/KG. CHANGES IN HEPATIC BLOOD FLOW WOULD NOT ALTER CLEARANCE.
PMID:512932 IGA T, KLAASSEN CD; J PHARMACOL EXP THER 211 (3): 690 (1979)
For more Absorption, Distribution and Excretion (Complete) data for INDOCYANINE GREEN (10 total), please visit the HSDB record page.
...INDOCYANINE GREEN...APPEARS IN BILE UNCHANGED
Patty, F. (ed.). Industrial Hygiene and Toxicology: Volume II: Toxicology. 2nd ed. New York: Interscience Publishers, 1963., p. 436
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): Indocyanine Green,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: Canisius-Wilhelmina Hospital | Isabelle Henskens | Noordwest Ziekenhuisgroep | Alrijne Hospital | Dijklander Ziekenhuis | Ziekenhuisgroep Twente | Diakonessenhuis, Utrecht | ZonMw
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 28, 2025
Lead Product(s) : Indocyanine Green,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Canisius-Wilhelmina Hospital | Isabelle Henskens | Noordwest Ziekenhuisgroep | Alrijne Hospital | Dijklander Ziekenhuis | Ziekenhuisgroep Twente | Diakonessenhuis, Utrecht | ZonMw
Deal Size : Inapplicable
Deal Type : Inapplicable
Indocyanine Green to Identify Sentinel Nodes During Breast Cancer Surgery
Details : Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2025
Details:
Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Thyroid Diseases.
Lead Product(s): Indocyanine Green,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Johns Hopkins University
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 23, 2025
Lead Product(s) : Indocyanine Green,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Johns Hopkins University
Deal Size : Inapplicable
Deal Type : Inapplicable
Intraoperative Parathyroid Gland (PTG) Identification Using a Hand-Held Imager (HHI)
Details : Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Thyroid Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 23, 2025
Details:
Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Brain Neoplasms.
Lead Product(s): Indocyanine Green,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 10, 2025
Lead Product(s) : Indocyanine Green,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Multi-center Study on CCeLL-In Vivo's Clinical Efficacy for Intraoperative Brain Tumor Diagnosis.
Details : Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Brain Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 10, 2025
Details:
Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Parathyroid Diseases.
Lead Product(s): Indocyanine Green,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Stryker
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 13, 2023
Lead Product(s) : Indocyanine Green,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Stryker
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Parathyroid Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 13, 2023
Details:
Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Stomach Ulcer.
Lead Product(s): Indocyanine Green,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Stryker
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 21, 2023
Lead Product(s) : Indocyanine Green,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Stryker
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Stomach Ulcer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 21, 2023
Details:
Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neck Pain.
Lead Product(s): Indocyanine Green,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Eva MedTech
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 14, 2023
Lead Product(s) : Indocyanine Green,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Eva MedTech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neck Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 14, 2023
Details:
Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cholecystitis, Acute.
Lead Product(s): Indocyanine Green,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 02, 2023
Lead Product(s) : Indocyanine Green,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Use of Indocyanine Green in Acute Cholecystitis
Details : Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cholecystitis, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 02, 2023
Details:
Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lung Neoplasms.
Lead Product(s): Indocyanine Green,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Olympus
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 26, 2022
Lead Product(s) : Indocyanine Green,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Olympus
Deal Size : Inapplicable
Deal Type : Inapplicable
Near-Infrared Perfusion During Minimally Invasive Thoracic Surgery Download
Details : Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lung Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 26, 2022
Details:
Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cubital Tunnel Syndrome.
Lead Product(s): Indocyanine Green,Inapplicable
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 18, 2022
Lead Product(s) : Indocyanine Green,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SPY Angiography To Assist With Ulnar Nerve Transposition at the Elbow
Details : Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cubital Tunnel Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 18, 2022
Details:
Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Lymphedema.
Lead Product(s): Indocyanine Green,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: National Institutes of Health | OnLume | National Cancer Institute
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 26, 2021
Lead Product(s) : Indocyanine Green,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : National Institutes of Health | OnLume | National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Intraoperative Evaluation of Axillary Lymphatics
Details : Indocyanine Green is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Lymphedema.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 26, 2021
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2035-08-04
US Patent Number : 10631746
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 211580
Patent Use Code : U-2815
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-08-04
Patent Expiration Date : 2029-02-11
US Patent Number : 8647605
Drug Substance Claim :
Drug Product Claim :
Application Number : 211580
Patent Use Code : U-2464
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-02-11
Patent Expiration Date : 2025-11-24
US Patent Number : 9421280
Drug Substance Claim :
Drug Product Claim :
Application Number : 211580
Patent Use Code : U-2467
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2025-11-24
Patent Expiration Date : 2028-06-04
US Patent Number : 8185176
Drug Substance Claim :
Drug Product Claim :
Application Number : 211580
Patent Use Code : U-2462
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2028-06-04
Patent Expiration Date : 2029-04-09
US Patent Number : 8406860
Drug Substance Claim :
Drug Product Claim :
Application Number : 211580
Patent Use Code : U-2463
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-04-09
Patent Expiration Date : 2025-11-24
US Patent Number : 9421280
Drug Substance Claim :
Drug Product Claim :
Application Number : 211580
Patent Use Code : U-2466
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2025-11-24
Patent Expiration Date : 2029-02-11
US Patent Number : 8647605
Drug Substance Claim :
Drug Product Claim :
Application Number : 211580
Patent Use Code : U-2468
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2029-02-11
Patent Expiration Date : 2039-07-14
US Patent Number : 11712320
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 211580
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-07-14
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
56
PharmaCompass offers a list of Indocyanine Green API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Indocyanine Green manufacturer or Indocyanine Green supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Indocyanine Green manufacturer or Indocyanine Green supplier.
PharmaCompass also assists you with knowing the Indocyanine Green API Price utilized in the formulation of products. Indocyanine Green API Price is not always fixed or binding as the Indocyanine Green Price is obtained through a variety of data sources. The Indocyanine Green Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Indocyanine Green manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Indocyanine Green, including repackagers and relabelers. The FDA regulates Indocyanine Green manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Indocyanine Green API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Indocyanine Green manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Indocyanine Green supplier is an individual or a company that provides Indocyanine Green active pharmaceutical ingredient (API) or Indocyanine Green finished formulations upon request. The Indocyanine Green suppliers may include Indocyanine Green API manufacturers, exporters, distributors and traders.
click here to find a list of Indocyanine Green suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Indocyanine Green DMF (Drug Master File) is a document detailing the whole manufacturing process of Indocyanine Green active pharmaceutical ingredient (API) in detail. Different forms of Indocyanine Green DMFs exist exist since differing nations have different regulations, such as Indocyanine Green USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Indocyanine Green DMF submitted to regulatory agencies in the US is known as a USDMF. Indocyanine Green USDMF includes data on Indocyanine Green's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Indocyanine Green USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Indocyanine Green suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Indocyanine Green Drug Master File in Korea (Indocyanine Green KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Indocyanine Green. The MFDS reviews the Indocyanine Green KDMF as part of the drug registration process and uses the information provided in the Indocyanine Green KDMF to evaluate the safety and efficacy of the drug.
After submitting a Indocyanine Green KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Indocyanine Green API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Indocyanine Green suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Indocyanine Green as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Indocyanine Green API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Indocyanine Green as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Indocyanine Green and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Indocyanine Green NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Indocyanine Green suppliers with NDC on PharmaCompass.
Indocyanine Green Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Indocyanine Green GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Indocyanine Green GMP manufacturer or Indocyanine Green GMP API supplier for your needs.
A Indocyanine Green CoA (Certificate of Analysis) is a formal document that attests to Indocyanine Green's compliance with Indocyanine Green specifications and serves as a tool for batch-level quality control.
Indocyanine Green CoA mostly includes findings from lab analyses of a specific batch. For each Indocyanine Green CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Indocyanine Green may be tested according to a variety of international standards, such as European Pharmacopoeia (Indocyanine Green EP), Indocyanine Green JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Indocyanine Green USP).